Little Green Pharma Ltd. · ASX:LGP
Little Green Pharma — Q3 FY2026 Earnings Presentation
17 slides from Little Green Pharma's earnings presentation, May 12, 2026
Slide 1: Quarterly & Appendix 4C Investor Presentation May 2026
March 2026 Quarterly & Appendix 4C ASX:LGP For personal use only Investor presentation MAY 2026 The most trusted medicinal cannabis brand
Slide 2: Disclaimer
Disclaimer Disclaimer Not financial product advice This presentation contains summary information about Little Green Pharma Ltd (ACN 615 586 215) (“LGP”) and its This document does not constitute financial product advice or take into account your investment activities current as at the date of this
Slide 3: Little Green Pharma
Little Green Pharma For personal use only 30t 5 BRANDS 39 PRODUCTS 4 FACILITIES PRODUCTION CAPACITY 11 13 SPONSORED 92 STAFF ACROSS 20+ STRAINS DISTRIBUTION TERRITORIES STUDIES / TRIALS 5 COUNTRIES GENETICS BANK
Slide 4: Revenue and cash receipts
Revenue and cash receipts For personal use only Cash receipts vs revenue ($000’s) 14,000 13,278 Annual results 13,000 Annual revenue of $42.4 million (unaudited), the highest 10,985 12,000 10,255 reported to date and up over 15% on prior year 11,000 12,547 Compound annual growth rate over the last f
Slide 5: Revenue by product category
Revenue by product category ($000’s) Revenue by 14,000 product category 12,000 10,000 For personal use only 8,000 6,000 Annual results Quarterly results 4,000 Flower sales of $30.5 million Record quarterly flower sales of 2,000 (unaudited), up over 30% on $10.0 million (unaudited), up prior year ove
Slide 6: Revenue by segment
Revenue by segment ($000’s) Revenue by 14,000 segment 12,000 10,000 For personal use only 8,000 6,000 Annual results 4,000 Record annual European sales of almost $16.0 million 2,000 (unaudited), up over 135% on prior year Australia annual sales of $26.4 million (unaudited), down - FY25Q4 FY26Q1 FY26
Slide 7: Revenue by brand
Revenue by brand For personal use only Revenue by brand ($000’s) 14,000 Annual results Quarterly results White label sales of $14.9 White label sales of $6.3 million 12,000 million (unaudited), up 240% (unaudited), up 105% on prior on prior year quarter predominantly due to white label flower sales
Slide 8: Net cashflows from operations
• Positive operating cashflows of $1.1 million, up from negative Net cashflows $1.0 million in prior quarter with over $6.0 million in receivables • Minimal increase in operating costs despite significant growth from operations in sales as well as Cannatrek merger transaction costs • LGP repaid $1.1
Slide 9: EV, NTA, cash, debt and revenue
EV, NTA, cash, debt and revenue For personal use only EV, NTA, cash, debt & revenue ($000’s) 100,000 100,000 Company’s net tangible assets continue to significantly exceed enterprise value 80,000 80,000 Minimal long-term debt of $2.6 million with $5.6 million in unused credit facilities 60,000 60,00
Slide 10: Merger timetable
Merger timetable Latest date for receipt of proxy forms and powers of attorney 20 May 2026 For personal use only Time and date for determining eligibility of LGP Shareholders to vote 20 May 2026 LGP Shareholder Meeting (Scheme Consideration Resolution) 22 May 2026 Second court hearing (approval of s
Slide 11: Merger strategic rationale
Merger strategic rationale • Immediate 3x revenue increase from $36.8m standalone base to $112.3m1 pro-forma based on FY2025 audited annual Immediate revenue accounts, creating a leading fully vertically integrated medicinal cannabis group with operations spanning cultivation, GMP- scaling certified
Slide 12: European market update
Germany European market A record 201 tonnes of cannabis flower was imported into Germany in CY25, update up 176% compared to the 73 tonnes imported in 20241 Q4CY25 was the first quarterly decline since 2024 (–4.1% vs. Q3), plausibly For personal use only driven by temporary suspension of BfArM impor
Slide 13: European market update (cont.)
European market Poland update (cont.) Poland's medical cannabis market demonstrated structural resilience after a telemedicine ban in late 2024 caused significant decline in volumes, with full recovery achieved by year-end 2025, supported by a For personal use only shift toward more professional cli
Slide 14: US medical cannabis markets
US medical cannabis markets In April 2026, medicinal cannabis was down- scheduled from Schedule I to Schedule III For personal use only LGP believes the milestone means the global cannabis Early growth phase Shake-out phase Growth phase Market maturity sector is progressing along the slope of enligh
Slide 15: Corporate overview
Corporate overview For personal use only Capital structure Shareholder structure Current share price1 $0.098 Shares outstanding1 ~306 million Options and performance rights on Issue2 ~31 million 24% Market capitalisation (undiluted) ~$30 million 37% Cash reserves (31 March 2026) ~$1.4 million 24% Lo
Slide 16: Delivering on strategy: the next months
THE NEXT 6 MONTHS Delivering on strategy For personal use only Subject to shareholder approval, transitioning to combined operations with Cannatrek from 1 June, including leveraging scale, accessing synergies through merger of clinics and wholesale operations, and unlocking latent asset capacity and
Slide 17: Q&A
For personal use only Q&A Paul Long, Managing Director A world of difference investor.littlegreenpharma.com
Little Green Pharma — Q3 FY2026 Earnings Presentation on 6ix